Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Weighted Average) (2016 - 2025)

Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 17 years, with the latest figure at $58.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.34% to $58.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $58.9 million, a 1.34% increase, with the full-year FY2025 number at $58.9 million, up 1.34% from a year prior.
  • Shares Outstanding (Weighted Average) hit $58.9 million in Q4 2025 for Vanda Pharmaceuticals, roughly flat from $59.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for VNDA hit a ceiling of $59.1 million in Q3 2025 and a floor of $55.1 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $57.2 million across 5 years, with a median of $57.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 2.49% in 2021 and later grew 1.31% in 2024.
  • Tracing VNDA's Shares Outstanding (Weighted Average) over 5 years: stood at $55.5 million in 2021, then rose by 1.64% to $56.5 million in 2022, then rose by 1.63% to $57.4 million in 2023, then grew by 1.34% to $58.1 million in 2024, then grew by 1.34% to $58.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for VNDA at $58.9 million in Q4 2025, $59.1 million in Q3 2025, and $58.8 million in Q2 2025.